Immuno oncology News and Research

RSS

Scientists reveal new method to reprogram specific T cells

When the immune system is imbalanced, either due to overly-active cells or cells that suppress its function, it causes a wide range of diseases, from psoriasis to cancer.

2 Aug 2017

Shaping the future of oncology treatment

Victories Over Cancer is about enabling those affected by cancer to enjoy more of life’s meaning full moments and making cancer more manageable. At Janssen, we're really thinking about the elimination of cancer, and we take a very deliberate approach to that.

2 Aug 2017

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

5 Jun 2017

Addressing unmet needs in prostate cancer

Prostate cancer is the second most diagnosed cancer globally with over a million men diagnosed worldwide. We are fortunate in that better diagnostic techniques and better awareness means that men are often being diagnosed earlier, which gives them a better chance of being cured.

19 Apr 2017

MSU and Venn Therapeutics develop promising therapy to delay B16 melanoma tumor growth

Michigan State University researchers presented promising cancer therapy results at the American Association for Cancer Research International Meeting in Washington, DC.

5 Apr 2017

Essen BioScience Launches the IncuCyte® S3 Live-Cell Analysis Platform

Essen BioScience, a pioneer and leader in the field of cell-based assays and instrumentation used for drug discovery and basic research, has launched the IncuCyte® S3 live-cell analysis platform for real-time, automated measurements of cell health, proliferation, movement and function directly inside a standard incubator.

From Sartorius 3 Apr 2017

Evolution of immuno-oncology

Immuno-oncology did not exist four years ago, it's a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology R&D. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).

13 Mar 2017

Sartorius to Acquire Real-Time Live-Cell Analysis Pioneer and Leader Essen BioScience

Sartorius, a leading partner to the biopharmaceutical industry and laboratories, today signed an agreement to acquire U.S. based Essen BioScience Inc.,

From Sartorius 6 Mar 2017

Essen Bioscience to Showcase IncuCyte® Live-cell Analysis System and Applications at AACR, Booth #1365

The IncuCyte® live-cell analysis platform from Essen BioScience will be showcased at the upcoming AACR conference, booth #1365.

From Sartorius 22 Feb 2017

ICLIO white paper spotlights top-level concerns in delivering immunotherapies for cancer

While momentum around immunotherapies for cancer continues to build, the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care.

19 Jan 2017

Essen BioScience’s IncuCyte live-cell analysis platform cited in more than 1000 publications

The IncuCyte live-cell analysis platform from Essen BioScience has been cited in more than 1000 peer-reviewed publications since its introduction.

From Sartorius 12 Jan 2017

Enterome, Bristol-Myers Squibb enter into Immuno-Oncology collaboration to identify new microbiome-derived biomarkers for cancer

Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer.

16 Nov 2016

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers.

11 Nov 2016

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer.

8 Aug 2016

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016

Merck partners with University of Nairobi to start medical oncology fellowship program for African doctors

Merck, a leading science and technology company, today announced to start the first Merck Africa Medical Oncology Fellowship Program for Sub-Saharan African countries in partnership with University of Nairobi, Kenya.

4 Jul 2016

Aspirin may increase likelihood of surviving colon cancer

It is well known that the drug ASA, also known internationally as Aspirin, has analgesic and fever-reducing properties. However, this drug may also increase the likelihood of surviving colon cancer.

10 Jun 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016.

20 May 2016

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Cancer immunology is all about how your immune cells are going to fight and kill your tumor cells. If you look at the pure genetic code of a T-cell that's going to kill your tumor compared to the same cell that has been “put-to-sleep” (by the tumor), the pure genetic DNA content of those two cells are identical.

From NanoString Technologies 11 May 2016

NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the introduction of nCounter Vantage, a portfolio of assays that power 3D Biology™ experiments in cancer research, including immuno-oncology.

From NanoString Technologies 19 Apr 2016